Compare Novo Nordisk A/S (NVO) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Zscaler Inc — how do they compare? Novo Nordisk A/S trades at $38.62 (market cap $165.31B), while Zscaler Inc trades at $233.5 (market cap $35.35B). The key difference: Novo Nordisk A/S is far larger — about 4.7× Zscaler Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Zscaler Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Zscaler Inc for 41 Days on average.
| NVO | ZS | |
|---|---|---|
Market Cap | $165.31B | $35.35B |
Volume | 11,432,838 | 3,726,203 |
Sector | Health | Technology |
52-Week High | $63.98 | $336.27 |
52-Week Low | $35.29 | $118.05 |
Typical Hold Time | 116 Days | 41 Days |
Enterprise Value | $179.56B | $33.73B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Zscaler (ZS) trades at $230.23, up 7.81% in the last 24 hours, with a bullish technical signal from moving averages. The company reported strong revenue growth, reaching $2.67 billion in 2025, and has beaten EPS estimates for three consecutive quarters. However, it remains unprofitable with a net income margin of -1.88%. Recent news includes a CRO transition and an upcoming Investor Day on October 6, 2026.
The outlook is mixed: robust revenue growth and AI-driven bookings offer upside, but profitability concerns and high valuation multiples pose risks. Analyst consensus is bullish with a $222.83 price target, though the stock trades above this level. Key risks include execution challenges and competitive pressures in cybersecurity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
